4.3 Article

Assessing main death pathways in T lymphocytes from HIV infected individuals

Journal

CYTOMETRY PART A
Volume 83A, Issue 7, Pages 648-658

Publisher

WILEY
DOI: 10.1002/cyto.a.22299

Keywords

CD4 T cells; CD8 T cells; caspases; HAART

Funding

  1. ICREA Funding Source: Custom

Ask authors/readers for more resources

Increased lymphocyte death is a hallmark of human immunodeficiency virus (HIV) infection. Although virological factors have been linked to this phenomenon, increased cell death rates are still observed in treated individuals in which viral replication is halted. To understand the nature of this remaining altered cell death, we have developed a simple and fast assay to assess major cell death pathways in lymphocytes isolated from HIV-infected individuals. The combination of three factors: (i) antibody staining to identify CD3+CD4+ and CD3+CD8+ cells, (ii) assessment of mitochondrial and plasma membrane function using DiOC6(3) or JC-1 probes and vital dyes, and (iii) caspase inhibition, allowed for the quantification of caspase-independent and -dependent cell death in CD4 and CD8 T cells. The latter mechanism was divided in intrinsic and extrinsic apoptotic pathways according to the sensitivity of the dissipation of mitochondrial membrane potential to Z-VAD-fmk or Q-VD-oPH treatment. Our data show similar results for both caspase inhibitors in treated infected individuals, whereas Q-VD-oPH showed a more potent inhibition in viremic individuals, yielding lower levels of intrinsic apoptosis. Comparison of DiOC6(3) and JC-1 probes yielded similar results in CD4 T cells, allowing for a clear definition of death mechanism in these cells. However, in CD8 T-cells, JC-1 showed heterogeneous staining and detected significantly lower levels of cell death with a higher contribution of intrinsic apoptosis. In conclusion, we provide a simple method to assess CD4 T-cell death mechanisms in HIV-infected individuals. The reasons and consequences of mitochondrial heterogeneity in CD8 T-cells require further evaluation. (c) 2012 International Society for Advancement of Cytometry

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Virology

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction

Clara Duran-Castells, Anuska Llano, Ai Kawana-Tachikawa, Anna Prats, Ignacio Martinez-Zalacain, Mie Kobayashi-Ishihara, Bruna Oriol-Tordera, Ruth Pena, Cristina Galvez, Sandra Silva-Arrieta, Bonaventura Clotet, Eva Riveira-Munoz, Esther Ballana, Julia. G. Prado, Javier Martinez-Picado, Jorge Sanchez, Beatriz Mothe, Dennis Hartigan-O'Connor, Tony Wyss-Coray, Andreas Meyerhans, Magnus Gisslen, Richard. W. Price, Carles Soriano-Mas, Jose Antonio Munoz-Moreno, Christian Brander, Marta Ruiz-Riol

Summary: High levels of SIRT2 are associated with uncontrolled HIV infection, plasma viral load, and proviral levels. SIRT2 levels are also linked to markers of neurological damage and brain involution, especially in individuals who initiate cART later. Inhibition of SIRT2 could potentially be a therapeutic target for HIV infections and their associated neurological dysfunction.

JOURNAL OF VIROLOGY (2023)

Article Oncology

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors

Eudald Felip, Edwards Pradenas, Margarita Romeo, Silvia Marfil, Benjamin Trinite, Victor Urrea, Ainhoa Hernandez, Ester Ballana, Marc Cucurull, Lourdes Mateu, Marta Massanella, Bonaventura Clotet, Teresa Moran, Julia Blanco

Summary: Patients with solid tumors have a higher risk of complications, hospitalizations, or death during the SARS-CoV-2 pandemic. The immunosuppressive state of cancer treatments or the tumor itself may affect the development of vaccination antibodies. This study emphasizes the importance of prioritizing cancer patients receiving anticancer treatment in SARS-CoV-2 vaccination programs.

MOLECULAR ONCOLOGY (2023)

Article Medicine, General & Internal

Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain.

Jordi Navarro, Adrian Curran, Berta Raventos, Jorge Garcia, Paula Suanzes, Vicente Descalzo, Patricia Alvarez, Nuria Espinosa, Marisa Luisa Montes, Ines Suarez-Garcia, Concha Amador, Roberto Muga, Vicenc Falco, Joaquin Burgos

Summary: In this study, researchers found a high prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in people living with HIV (PLWH). Obesity and diabetes were associated factors with NAFLD, while exposure to integrase strand transfer inhibitors reduced the risk. Moreover, among patients with hepatic steatosis, exposure to thymidine analogues increased the risk of significant fibrosis, while exposure to non-nucleoside reverse transcriptase inhibitors reduced this risk.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2023)

Review Virology

Opportunities for CAR-T Cell Immunotherapy in HIV Cure

Gerard Campos-Gonzalez, Javier Martinez-Picado, Talia Velasco-Hernandez, Maria Salgado

Summary: Chimeric antigen receptor (CAR) technology has had a significant impact on the treatment of blood malignancies, particularly various types of leukemia. However, applying this technology to HIV treatment presents numerous challenges that hinder its widespread adoption.

VIRUSES-BASEL (2023)

Article Multidisciplinary Sciences

Phenotypic characterization of single CD4+T cells harboring genetically intact and inducible HIV genomes

Caroline Dufour, Corentin Richard, Marion Pardons, Marta Massanella, Antoine Ackaoui, Ben Murrell, Bertrand Routy, Rejean Thomas, Jean-Pierre Routy, Remi Fromentin, Nicolas Chomont

Summary: The phenotypic diversity of HIV-infected cells persisting during antiretroviral therapies (ART) was investigated. CD4+ T cells expressing integrin VLA-4 were found to be enriched in replication-competent HIV. Clonally expanded cells with identical proviruses displayed diverse phenotypes, indicating the role of cellular proliferation in the phenotypic diversification of the HIV reservoir. Genetically intact and inducible viral genomes were associated with higher levels of VLA-4 expression in CD4+ T cells. Replication-competent HIV was highly enriched in memory CD4+ T cells expressing high levels of VLA-4.

NATURE COMMUNICATIONS (2023)

Review Immunology

Syphilis vaccine: challenges, controversies and opportunities

Carlos Avila-Nieto, Nuria Pedreno-Lopez, Oriol Mitja, Bonaventura Clotet, Julia Blanco, Jorge Carrillo

Summary: Syphilis is a sexually or vertically transmitted disease caused by Treponema pallidum subspecie pallidum (TPA) infection. Despite being an obligate human pathogen with a well-known infection route and effective treatment options, the incidence of syphilis has been increasing. Developing a syphilis vaccine is crucial in countries where current preventive measures are limited. Although previous vaccine prototypes in preclinical studies did not provide full protection against infection, they showed promising results in preventing bacteria dissemination and attenuating lesion development. It is important to integrate knowledge about TPA immune response and outer membrane protein (OMP) characterization to expedite vaccine development.

FRONTIERS IN IMMUNOLOGY (2023)

Article Medicine, General & Internal

Macrophage CD5L is a target for cancer immunotherapy

Lidia Sanchez-Moral, Tony Paul, Clara Martori, Joan Font-Diaz, Lucia Sanjurjo, Gemma Aran, Erica Tellez, Julia Blanco, Jorge Carrillo, Masaoki Ito, Martina Tuttolomondo, Henrik J. Ditzel, Caterina Fumagalli, Gustavo Tapia, Julia Sidorova, Helena Masnou, Marco-Antonio Fernandez-Sanmartin, Juan-Jose Lozano, Cristina Vilaplana, Alheli Rodriguez-Cortes, Carolina Armengol, Annabel F. Valledor, Leonor Kremer, Maria-Rosa Sarriasa

Summary: This study explores the role of macrophage CD5L protein in tumor-associated macrophage (TAM) activity and its potential as a therapeutic target. Results show that cancer cell lines induce an immunosuppressive phenotype in macrophages through increased CD5L expression. High TAM expression of CD5L is associated with poor patient outcomes in lung adenocarcinoma. Researchers developed an anti-CD5L monoclonal antibody that blocks the immunosuppressive phenotype in macrophages and inhibits tumor progression in vivo.

EBIOMEDICINE (2023)

Article Immunology

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

Ferran Tarres-Freixas, Carmen Aguilar-Gurrieri, Maria Luisa Rodriguez de la Concepcion, Victor Urrea, Benjamin Trinite, Raquel Ortiz, Edwards Pradenas, Pau Blanco, Silvia Marfil, Luis Manuel Molinos-Albert, Ana Barajas, Anna Pons-Grifols, Carlos Avila-Nieto, Ismael Varela, Laura Cervera, Sonia Gutierrez-Granados, Maria Mercedes Segura, Francesc Godia, Bonaventura Clotet, Jorge Carrillo, Julia Blanco

Summary: This study engineered a HIV-1 Gag-based VLP platform with increased antigen density on the surface, resulting in highly immunogenic MinGag-VLPs. Immunization with these VLPs induced strong humoral responses and demonstrated functional effects in halting tumor progression in vivo mouse model.

NPJ VACCINES (2023)

Article Multidisciplinary Sciences

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization

Edwards Pradenas, Silvia Marfil, Victor Urrea, Macedonia Trigueros, Tetyana Pidkova, Anna Pons-Grifols, Raquel Ortiz, Carla Rovirosa, Ferran Tarres-Freixas, Carmen Aguilar-Gurrieri, Ruth Toledo, Anna Chamorro, Marc Noguera-Julian, Lourdes Mateu, Ignacio Blanco, Eulalia Grau, Marta Massanella, Jorge Carrillo, Bonaventura Clote, Benjamin Trinite, Julia Blanco

Summary: The development of cross-variant neutralizing antibodies against SARS-CoV-2 is an important goal for COVID-19 vaccine strategies. This study analyzed the neutralization titers of plasma from different groups based on vaccine doses and infection history. Two doses of vaccine had limited efficacy in generating cross-neutralizing antibodies against Omicron variants in uninfected individuals, but showed synergy with natural immunization in convalescent individuals. Booster doses significantly broadened the cross-neutralizing response in uninfected individuals and improved responses in convalescent individuals. Omicron breakthrough infections also improved cross-neutralization in vaccinated individuals. Overall, ancestral Spike-based immunization, through infection or vaccination, helps broaden SARS-CoV-2 humoral immunity.

ISCIENCE (2023)

Article Infectious Diseases

Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes

Paula Suanzes, Jordi Navarro, Ariadna Rando-Segura, Patricia Alvarez-Lopez, Jorge Garcia, Vicente Descalzo, Arnau Monforte, Maider Arando, Lucia Rodriguez, Bibiana Planas, Joaquin Burgos, Adrian Curran, Maria Jose Buzon, Vicenc Falco

Summary: This study aimed to investigate the impact of starting antiretroviral therapy (ART) within the first 30 days after acquiring HIV infection on immunovirological response. The results showed that patients who started ART very early or early and were treated with INSTI-based regimens achieved immune recovery earlier. The CD4+/CD8+ ratio before ART initiation and the use of INSTI-based regimens were the strongest predictors of immune recovery.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

Alexandra Moros, Antoni Prenafeta, Antonio Barreiro, Eva Perozo, Alex Fernandez, Manuel Canete, Luis Gonzalez, Carme Garriga, Edwards Pradenas, Silvia Marfil, Julia Blanco, Paula Cebollada Rica, Marta Sistere-Oro, Andreas Meyerhans, Teresa Prat Cabanas, Ricard March, Laura Ferrer

Summary: The development of a new generation of efficacious vaccines is crucial due to the high global incidence of COVID-19 and low vaccination rates. Researchers have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein fusion of the receptor binding domain (RBD) from the Beta variant of SARS-CoV-2 and the equivalent domain from the Alpha variant. In pig models, PHH-1V has demonstrated excellent safety and has induced a robust immune response to SARS-CoV-2, including neutralising antibodies to multiple variants.

VACCINE (2023)

Article Immunology

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Lorna Leal, Judit Pich, Laura Ferrer, Jocelyn Nava, Ruth Marti-Lluch, Ignasi Esteban, Edwards Pradenas, Dalia Raich-Regue, Antoni Prenafeta, Karla Escobar, Carmen Pastor, Marc Ribas-Aulinas, Benjamin Trinite, Jordana Munoz-Basagoiti, Gemma Domenech, Bonaventura Clotet, Julia Corominas, Aida Corpes-Comes, Carme Garriga, Antonio Barreiro, Nuria Izquierdo-Useros, Joan Albert Arnaiz, Alex Soriano, Jose Rios, Marga Nadal, Montserrat Plana, Julia Blanco, Teresa Prat, Elia Torroella, Rafel Ramos, Eva Bonfill, Omar Anagua, Faisury Caicedo, Clara Castan, Fauno Guazina, Sara Messeguer, Marta Aldea, Anna Vilella, Sandra Serrano, Lorna Leal, Judit Pich, Jocelyn Nava, Karla Escobar, Joan Albert Arnaiz, Alex Soriano, Jose Rios, Teresa Botta, Ignasi Esteban, Carmen Pastor, Montserrat Plana, Gemma Domenech, Silvia Marfil, Carla Rovirosa, Raquel Ortiz, Daniel Perez-Zsolt, Marcal Gallemi, Edwards Pradenas, Dalia Raich-Regue, Benjamin Trinite, Jordana Munoz-Basagoiti, Bonaventura Clotet, Nuria Izquierdo-Useros, Julia Blanco, Marina Gonzalez del Rio, Ruth Marti-Lluch, Marc Ribas-Aulinas, Aida Corpes-Comes, Marga Nadal, Rafel Ramos, Luis Gonzalez, Manuel Canete, Laia Madrenas, Alexandra Moros, Irina Gueell, Laura Ferrer, Antoni Prenafeta, Julia Corominas, Carme Garriga, Antonio Barreiro, Teresa Prat, Elia Torroella

Summary: This study reports the safety, tolerability, and immunogenicity of a recombinant protein vaccine against SARS-CoV-2. The vaccine formulations were found to be safe and well tolerated, and induced strong humoral immune responses. This research has contributed significantly to the further development of the vaccine.

NPJ VACCINES (2023)

Article Multidisciplinary Sciences

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

Antoni Prenafeta, Gregori Bech-Sabat, Alexandra Moros, Antonio Barreiro, Alex Fernandez, Manuel Canete, Merce Roca, Luis Gonzalez-Gonzalez, Carme Garriga, Joachim Confais, Marion Toussenot, Hugues Contamin, Andres Pizzorno, Manuel Rosa-Calatrava, Edwards Pradenas, Silvia Marfil, Julia Blanco, Paula Cebollada Rica, Marta Sistere-Oro, Andreas Meyerhans, Cristina Lorca, Joaquim Segales, Teresa Prat, Ricard March, Laura Ferrer

Summary: SARS-CoV-2 emerged in December 2019 and continues to spread, necessitating the development of accessible second-generation vaccines. The PHH-1V vaccine candidate, previously developed, shows efficacy in cynomolgus macaques by inducing high levels of antibodies and cellular immune response. Vaccination with PHH-1V prevents viral replication and reduces viral load in respiratory tracts after experimental infection, suggesting its potential use in humans.

ISCIENCE (2023)

Article Hematology

Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration

Francisco Belda, Oscar Mora, Monica Lopez-Martinez, Nerea Torres, Ana Vivanco, Silvia Marfil, Edwards Pradenas, Marta Massanella, Julia Blanco, Rebecca Christie, Michael Crowley

Summary: This observational study characterizes the generation of antibodies against SARS-CoV-2 spike protein after vaccination with different COVID-19 vaccines and their neutralizing activity. Age and prior SARS-CoV-2 infection affect the vaccine response. The findings are important for understanding vaccine efficacy and developing antibody assays.

PLASMATOLOGY (2023)

No Data Available